Benign Prostatic Hyperplasia Prevention: Scoping Review with ☸️SAIMSARA
Abstract
This scoping review aims to systematically map and synthesize the current evidence from experimental and clinical studies on the prevention of benign prostatic hyperplasia (BPH), identifying key modifiable risk factors, protective pathways, and emerging therapeutic targets. The review uses 46 references and builds its evidence map from 24 original studies with 294063 total participants/sample observations (topic-deduplicated ΣN). The evidence mapped in this review indicates that BPH prevention is most coherently framed as the management of systemic metabolic and inflammatory health, rather than a prostate-isolated process. Recurrent signals support a protective role for favorable lipid profiles, with HDL cholesterol associated with a 17% lower risk (HR=0.83), and an elevated risk linked to metabolic dysfunction, inflammation, and frailty trajectories, where high-increasing frailty conferred nearly 3-fold higher risk (OR 2.82). Preclinical work on antioxidant and anti-inflammatory compounds further highlights converging mechanisms, though human preventive efficacy remains unproven. Clinically, this suggests integrating metabolic, inflammatory, and lifestyle assessment into BPH risk stratification for aging men. Future randomized trials should test whether targeted modulation of metabolic-inflammatory pathways translates into measurable reductions in BPH incidence and progression.
Read the paper
Related studies
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
- Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
- Long-term outcomes after treatment with Optilume BPH: Four-year results from the EVEREST study
- Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.